Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
This study is intended to evaluate the potential 2-way reciprocal interaction between
 multiple doses of Epanova™ and a single dose of rosuvastatin
The PK of rosuvastatin will be monitored following single-dose administration of rosuvastatin
 with and without multiple-dose administration of 4 g Epanova™ for 13 consecutive days in
 order to detect a possible interaction between rosuvastatin and Epanova™. The PK of total
 EPA, total DHA and total EPA+DHA will also be monitored following multiple-dose
 administration of Epanova™ with and without single-dose administration of 40 mg rosuvastatin.
 A single dose administration for rosuvastatin has been judged sufficient to yield plasma
 concentrations that will be detectable with an adequate validated analytical method and
 characterize adequately the PK of rosuvastatin.
Inclusion Criteria:

 -  Male or female (non-childbearing potential)

 -  Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening

 -  Non-smoker

 -  Medically healthy with no clinically significant laboratory profiles, vital signs or
 ECGs

 Exclusion Criteria:

 -  mentally or legally incapacitated or has significant emotional problems at the time of
 screening visit or expected during the conduct of the study

 -  History or presence of myopathy and/or hypothyroidism.

 -  History or presence of transaminase elevations

 -  History or presence of hypersensitivity or idiosyncratic reaction to rosuvastatin, to
 other HMG-CoA reductase inhibitors, to Epanova™, to Vascepa®, or to related compounds

 -  Known sensitivity or allergy to soybeans, fish, and/or shellfish.

 -  Has consumed fish within 7 days prior to check-in.

 -  Female subjects who are pregnant or lactating.

 -  Positive urine drug and alcohol results at screening or check-in.

 -  Positive urine cotinine at screening and check-in

 -  Use of any drugs known to be inducers of CYP enzymes and/or P-gp

 -  Donation of blood or significant blood loss within 56 days prior to the first dose of
 study medication.

 -  Plasma donation within 7 days prior to the first dose of study medication.

 -  Participation in another clinical trial within 28 days prior to the first dose of
 study medication.